Перегляд за Автор "Chopyak, V. V."

Зараз показуємо 1 - 2 з 2
  • Ескіз недоступний
    Документ
    Peculiarities of TLR9 expression on immune competent cells in reactive arthritis patients with chronic Epstein-Barr virus infection
    (Полтавський державний медичний університет, 2020) Lomikovska, M. P.; Hauduchok, I. G.; Potomkina, H. O.; Zubchenko, S. O.; Krill, I. Y.; Ischeykin, K. Y.; Chopyak, V. V.; Ламіковська, М. П.; Гайдучок, І. Г.; Потьомкіна, Г. О.; Зубченко, С. О.; Кріль, І. Й.; Іщейкін, Костянтин Євгенович; Чопяк, В. В.; Ламиковская, М. П.; Гайдучок, И. Г.; Потёмкина, Г. О.; Зубченко, С. О.; Криль, И. Й.; Ищейкин, Константин Евгеньевич; Чопяк, В. В.
    The work presents the study findings on the TLR9 expression in immune competent cells in reactive arthritis patients with chronic Epstein-Barr virus infection, and considers the possibility of the reactive arthritis transformation into rheumatoid arthritis. It was established that expression of TLR9+CD123+ on monocytes was reliably higher in the blood of reactive arthritis patients as compared to healthy individuals, while in patients in active phase of EBV-infection the expression of this receptor was reliably higher as compared to similar indices of patients at the latent phase. At that, the number of TLR9+CD123+-monocytes in patients with reactive and rheumatoid arthritis was not reliably different. The number of TLR9+CD123+-lymphocytes as compared to indices of healthy individuals was reliably higher in patients with rheumatoid arthritis at both phases of chronic EBV-infection, while in patients with reactive arthritis it was only characteristic at the active phase of the infection. Expression of this receptor on lymphocytes turned out to be reliably higher in patients with rheumatoid arthritis as compared to patients with reactive arthritis, particularly at the active phase of chronic EBV infection.
  • Ескіз
    Документ
    Pharmacoeconomic approaches for pharmacotherapy of rheumatoid arthritis
    (Національна медична академія післядипломної освіти імені Шупика, Інформаційно-науковий центр "Лікарська справа", 2021) Hayduchok, I. G.; Shapovalova, V. O.; Ishcheikin, K. E.; Chopyak, V. V.; Shapovalov, V. V.; Shapovalov, V. V.; Гайдучок, І. Г.; Шаповалова, В. О.; Іщейкін, Костянтин Євгенович; Чопяк, В. В.; Шаповалов, В. В. (мол.); Шаповалов, В. В.
    With the spread of the coronavirus pandemic, the role of pharmacotherapy of rheumatoid arthritis (RA) among patients with dual health disorders and in patients with systemic diseases is growing. This article is devoted to pharmacoeconomic for the pharmacotherapy of RA based on ABC/VEN analysis. Materials and methods. International and national medical and technological documents on standardization of medical care of RA, as well as scientific sources were used for regulatory, documentary and pharmacoeconomic analysis. ABC analysis was performed as a tool to study the cost of purchasing drugs. VEN analysis was performed to classify drugs into categories V, E and N on the principles of evidence-based medicine, forensic pharmacy, evidence-based pharmacy. Results. On thefirst stage of the research was conducted clinical and pharmacological analysis, the next stages – marketing and pharmacoeconomic analysis. Based on the ABC/VEN analysis, a matrix of the consolidated ABC/VEN analysis was developed. Discussion. The largest share (66.7 %) falls on the ATC classification code L “Antineoplastic and immunomodulatory agents”. According to the results of marketing analysis tablets occupy 50 % of doctors’ appointments; 75 % of the studied drugs have an unlimited validity of registration certificates. Ranking of country of origin of manufacturers of studied drugs: Germany – 37.6 %. Category A included five drugs’ INN (Mycophenolic acid, Azathioprine, Cyclophosphamide, Methotrexate, Ciclosporine), the cost of one dose is 5241.1 UAH, which is 78.12 % of the total cost of treatment for a patient with RA. It was found that six drugs INN (Methotrexate, Sulfasalazine, Hydroxychloroquine, Azathioprine, Ciclosporine, Cyclophosphamide) belong to category V (Vital). Conclusion. The introduction of information about pharmacoeconomic for pharmacotherapy of RA in the activities of health care institutions will ensure proper organization of the order of drug circulation at the stages of prescribing, prescribing, storage, accounting, quality control, transportation, release, destruction, licensing in accordance with current medical and pharmaceutical legislation.